Local response to hypofractionated radiotherapy combined with systemic therapy predicts survival in advanced breast cancer: a retrospective cohort study

Abstract Purpose The role of hypofractionated radiotherapy (HFRT) in advanced breast cancer beyond symptom palliation remains underexplored. This study evaluated the efficacy, safety, and prognostic factors of local HFRT combined with systemic therapy, with exploratory tissue-based genomic profiling. Methods This retrospective cohort included 67 advanced breast cancer patients who received HFRT (≥ 5 Gy/fraction, ≤ 10 fractions) to metastatic lesions between 2021 and 2026. Objective response rate (ORR), progression-free survival (PFS), time to next systemic therapy (TTNT), overall survival (OS), and adverse events (AEs) were assessed. Subgroup analyses were performed, and tumor sequencing was performed in 19 patients for somatic mutation analysis. Results The local ORR was 62.7%, with median local PFS of 8.0 months, overall PFS of 6.2 months, TTNT of 6.6 months, and OS of 19.1 months. Local response was independently associated with improved PFS (HR 0.31, 95%CI 0.16–0.59, P < 0.001) and OS (HR 0.29, 95%CI 0.15–0.58, P = 0.001). Liver metastasis was associated with lower response and worse survival. Deeper tumor shrinkage (≥ 50%) among responders was not significantly associated with additional survival benefits. AEs were manageable, with no grade 4–5 events. Common somatic mutations included TP53 (63.2%), PIK3CA (42.1%), and PTEN (36.8%), with no significant associations identified between individual gene mutations and ORR. Conclusion Local HFRT combined with systemic therapy showed favorable efficacy and safety in advanced breast cancer, with local response identified as a strong factor associated with survival benefit. However, no significant association was observed between deeper tumor shrinkage and additional survival benefits.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-11-14
DOI
https://doi.org/10.1007/s00432-026-06665-9
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Local response to hypofractionated radiotherapy combined with systemic therapy predicts survival in advanced breast cancer: a retrospective cohort study

Yiqi Yang, Li Xie, Ruihan Xu, Shanbao Gao et al.
Journal of Cancer Research and Clinical Oncology
Breast Cancer Treatment Studies
article

Local response to hypofractionated radiotherapy combined with systemic therapy predicts survival in advanced breast cancer: a retrospective cohort study

Yiqi Yang, Li Xie, Ruihan Xu, Shanbao Gao, Tingting Yan, Yixuan Wang, Xinyi Shen, Fang Yang
article en

Abstract

Abstract Purpose The role of hypofractionated radiotherapy (HFRT) in advanced breast cancer beyond symptom palliation remains underexplored. This study evaluated the efficacy, safety, and prognostic factors of local HFRT combined with systemic therapy, with exploratory tissue-based genomic profiling. Methods This retrospective cohort included 67 advanced breast cancer patients who received HFRT (≥ 5 Gy/fraction, ≤ 10 fractions) to metastatic lesions between 2021 and 2026. Objective response rate (ORR), progression-free survival (PFS), time to next systemic therapy (TTNT), overall survival (OS), and adverse events (AEs) were assessed. Subgroup analyses were performed, and tumor sequencing was performed in 19 patients for somatic mutation analysis. Results The local ORR was 62.7%, with median local PFS of 8.0 months, overall PFS of 6.2 months, TTNT of 6.6 months, and OS of 19.1 months. Local response was independently associated with improved PFS (HR 0.31, 95%CI 0.16–0.59, P < 0.001) and OS (HR 0.29, 95%CI 0.15–0.58, P = 0.001). Liver metastasis was associated with lower response and worse survival. Deeper tumor shrinkage (≥ 50%) among responders was not significantly associated with additional survival benefits. AEs were manageable, with no grade 4–5 events. Common somatic mutations included TP53 (63.2%), PIK3CA (42.1%), and PTEN (36.8%), with no significant associations identified between individual gene mutations and ORR. Conclusion Local HFRT combined with systemic therapy showed favorable efficacy and safety in advanced breast cancer, with local response identified as a strong factor associated with survival benefit. However, no significant association was observed between deeper tumor shrinkage and additional survival benefits.

Journal of Cancer Research and Clinical Oncology
Nanjing Drum Tower Hospital (CN)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon